Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group Inc (MDXG) delivers innovative regenerative biologics for advanced wound care and surgical recovery, leveraging human placental tissue allografts and proprietary processing technologies. This news hub provides stakeholders with verified updates about the company's operational milestones, clinical advancements, and regulatory engagements.
Investors and medical professionals will find a comprehensive repository of press releases detailing financial results, product launches, and research developments. Key coverage areas span quarterly earnings disclosures, FDA regulatory updates, strategic partnership announcements, and clinical study publications validating MDXG's biomaterial solutions.
All content is curated to maintain factual accuracy and timeliness, with direct links to official SEC filings and peer-reviewed research. The resource emphasizes MDXG's patented Purion® processing methodology and its applications in chronic wound management across healthcare settings.
Bookmark this page for streamlined access to MiMedx's latest developments in therapeutic biologics, including innovations in xenograft solutions and digital platforms enhancing clinical workflow efficiency. Regular updates ensure informed tracking of the company's progress in regenerative medicine markets.
MIMEDX has appointed Kim Moller as Chief Commercial Officer (CCO), effective June 26, 2024. Moller, previously Senior Vice President of Sales since August 2020, will now oversee marketing and international commercial operations. CEO Joseph H. Capper praised Moller's leadership in transforming MIMEDX's commercial organization into a high-performing team. Moller brings nearly 30 years of sales leadership experience from reputable firms such as 3M, Acelity, and KCI. She holds a BSN from the University of Phoenix and an MBA from Colorado Christian University.
MiMedx Group (Nasdaq: MDXG) announced participation in two upcoming investor conferences. Senior management will attend the Craig-Hallum 21st Annual Institutional Investor Conference on May 29, 2024, at the Renaissance Minneapolis Hotel in Minneapolis, MN. They will also be present at the Northland Growth Conference 2024 on June 25, which will be held virtually. Investors can arrange meetings with senior management by contacting their respective Craig-Hallum or Northland representatives.
MiMedx Group, Inc. (Nasdaq: MDXG) announced first quarter 2024 results with net sales of $85 million, 18% growth year-over-year, GAAP net income of $9 million, adjusted EBITDA of $19 million, and other notable achievements like portfolio expansion and new directors.
FAQ
What is the current stock price of Mimedx Group (MDXG)?
What is the market cap of Mimedx Group (MDXG)?
